These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial. Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L; JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037 [TBL] [Abstract][Full Text] [Related]
5. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. Windecker S; Wahl A; Nedeltchev K; Arnold M; Schwerzmann M; Seiler C; Mattle HP; Meier B J Am Coll Cardiol; 2004 Aug; 44(4):750-8. PubMed ID: 15312853 [TBL] [Abstract][Full Text] [Related]
6. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism. Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921 [TBL] [Abstract][Full Text] [Related]
7. Recurrent events after percutaneous closure of patent foramen ovale. Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325 [TBL] [Abstract][Full Text] [Related]
8. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W; Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390 [TBL] [Abstract][Full Text] [Related]
9. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial. Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM; Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434 [TBL] [Abstract][Full Text] [Related]
10. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. Hung J; Landzberg MJ; Jenkins KJ; King ME; Lock JE; Palacios IF; Lang P J Am Coll Cardiol; 2000 Apr; 35(5):1311-6. PubMed ID: 10758974 [TBL] [Abstract][Full Text] [Related]
11. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. Wahl A; Krumsdorf U; Meier B; Sievert H; Ostermayer S; Billinger K; Schwerzmann M; Becker U; Seiler C; Arnold M; Mattle HP; Windecker S J Am Coll Cardiol; 2005 Feb; 45(3):377-80. PubMed ID: 15680715 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism. Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959 [TBL] [Abstract][Full Text] [Related]